Wegovy Injections for Weight Loss

Our medical weight loss center has Wegovy in stock and can ship to your door after having a consult with one of our weight loss specialists. Our compounded semaglutide injections are the best on the market. Our physicians will follow up with you to make sure you are losing the weight that you want without the unwanted side effects.

Wegovy Injections For Weight Loss

Wegovy in stock near me


Losing weight and keeping it off is a struggle for many patients. At Weight Loss Clinic Los Angeles, we understand the frustration of our patients, and we’re here to help. Under the expert care of Dr. David Nazarian, we provide customized plans combining Bioidentical Hormone Replacement Therapy (BHRT) with the latest medical therapies for sustained weight loss.


Our special pharmacy compounded Wegovy injection is in stock and can be shipped to your door if you qualify for this weight loss injection.  Wegovy, is approved specifically for weight management in adults. Wegovy works by tapping into appetite signaling pathways, helping patients feel satiated with less food intake. In clinical trials, over 60% of patients have achieved over 15% body weight reduction with Wegovy over a year or more, a level far exceeding other therapies.


What is Wegovy?


Wegovy (semaglutide) is approved for use in adults with obesity or overweight with at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.


Approved by the FDA, Wegovy works by mimicking a hormone called GLP-1 that targets areas of the brain that regulate appetite and food intake. It helps a person feel full sooner and for longer, leading them to eat less. It also slows stomach emptying to promote fullness.


In a clinical study, people taking Wegovy lost, on average, 5-20% of their body weight over 68 weeks when used along with diet and exercise [1]. Like other weight loss medications, it’s meant to be used along with lifestyle changes.


Understanding Wegovy (Semaglutide) and Its Mechanism


Wegovy contains the active drug semaglutide, which belongs to a class of medications called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1, which is a hormone released naturally in the body after eating [2].

GLP-1 has several effects that together promote weight loss:

  1. Slows stomach emptying: By slowing the rate at which food empties from your stomach into the small intestine, it helps you feel fuller longer after meals. This controls hunger.
  1. Increases satiety signals: It activates receptors in the brain that control feelings of fullness and satiety or satisfaction from food. This helps curb excessive eating.
  1. Lowers appetite: It reduces appetite signals in areas of the brain like the hypothalamus and brain stem, which regulate food intake behavior. People have less motivation to eat more.
  2. Regulates blood sugar: It balances blood sugar levels by stimulating insulin when blood sugar is high while also inhibiting the release of glucagon, which raises blood sugar. This helps control diabetes.

Efficacy and Benefits of Wegovy Injections


Wegovy has been shown to be quite effective for weight loss in clinical trials, leading to significant reductions in body weight and BMI along with other health benefits when used properly:

Study 1 (1,961 adults):

  • Wegovy users lost an average of 15% of their body weight after 68 weeks.
  • Placebo users only lost about 2% of their body weight.
  • 84% of Wegovy users achieved at least a 5% weight loss, compared to 31% with placebo.

Study 2 (611 adults with counseling):

  • Wegovy users lost an average of 16% of their body weight after 68 weeks.
  • Placebo users lost around 6% of their body weight.
  • 85% of Wegovy users achieved at least a 5% weight loss, compared to 48% with placebo.

Study 3 (902 adults maintaining weight loss):

  • Wegovy users continued losing weight, with an additional 8% reduction in body weight after 48 more weeks.
  • Placebo users regained 7% of their body weight after stopping Wegovy, indicating the need to continue Wegovy to avoid weight regain.

Type 2 Diabetes Patients Study:

Study 4 (1,210 adults with type 2 diabetes):

  • Wegovy users lost an average of 10% of their body weight after 68 weeks.
  • Placebo users only lost about 3% of their body weight.
  • 67% of Wegovy users achieved at least a 5% weight loss, compared to 30% with placebo.

Adolescent Study:

Adolescent Study (200 participants aged 12 to less than 18 years):

  • Those treated with Wegovy experienced a BMI drop by an average of 16% after 68 weeks [3].
  • Participants who received a placebo had an average BMI increase of less than 1%.
  • About 73% of Wegovy users lost at least 5% of their weight, while around 18% of placebo users achieved the same.

Wegovy where to buy

Contact us at 424-283-4273 and schedule a consult with one of our health care providers. We will then go over your medical history and make sure you are a candidate for this weight loss injection. Once you are deemed safe, our medical office can send out the medication directly to your home. Our nursing staff will follow up with you to make sure you receive the proper care and are losing weight safely and without any unwanted side effects.

How it works

Contact us at +1 424-283-4273 to schedule an in office consult or virtual consult

or Book Online to receive your prescription of Wegovy or other Semaglutide or Trizepatide for weight loss.

  • Virtual Consult with MD & Nutritionist $450
  • 3 Month Supply of the best compounded semaglutide injection  $750 ( Special Pricing) 
  • Follow Ups $250
  • Lose 10 – 20% of body fat safely and effectively
Dr. David Nazarian

Safety Profile and Potential Side Effects


Most people won’t get side effects from Wegovy. The most common ones are:

  • Nausea and vomiting [4].
  • Diarrhea
  • Stomach pain
  • Allergic reactions
  • Inflammation of the pancreas
  • Constipation
  • Tiredness

Administration and Dosage Guidelines


Here are some key points about properly administering and dosing Wegovy:


  • Wegovy comes as a prefilled, single-dose pen that is injected under the skin (subcutaneous injection) of the abdomen, thigh, or upper arm
  • Prior to use, the pen should be stored in the refrigerator between 36°F to 46°F (2°C to 8°C)
  • Allow pen to reach room temperature for 10-15 minutes before injecting
  • Injection sites should be rotated each week to avoid irritation and changes under skin

Dosing Guidelines:

  • The starting dose is 0.25 mg, taken once weekly by subcutaneous injection
  • The dose is increased gradually over a period of 16-20 weeks up to a maximum dose of 2.4 mg once weekly

Dose escalation schedule:


– 0.25 mg weekly for the first 4 weeks

– 0.5 mg weekly next 4 weeks

– 1 mg weekly for 4 more weeks

– Then, 2.4 mg weekly maintenance dose


  • If dose escalation causes tolerability issues like gastrointestinal side effects, the delay increases by 4 weeks.
  • If a dose is missed, it can be taken within 3 days of the scheduled day. If more than 3 days, skip the missed dose and take the next scheduled dose.
  • Treatment is intended to be long-term to maintain weight loss effects over time.
  • Following the administration instructions and gradual dose escalation schedule helps improve the safety and tolerability of Wegovy for chronic weight management.

Patient Eligibility and Considerations


Patient Eligibility and Considerations

Here are some key patient eligibility factors and additional considerations regarding the use of Wegovy (Semaglutide) for weight management:

Patient Eligibility:

  • Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia [5].
  • Patients who have not achieved sufficient weight loss or who have plateaued during an initial weight management program focusing on diet, exercise, and lifestyle changes

Additional Considerations:

  • Wegovy’s effects on weight loss and weight-related comorbidities appear greater in patients with type 2 diabetes.
  • Efficacy has also been demonstrated in adolescents aged 12 and older, though not yet approved for this population.
  • Kidney and liver function may need periodic monitoring during treatment.
  • Wegovy should not be used in those with a personal or family history of medullary thyroid carcinoma or patients with Multiple Endocrine Neoplasia syndrome type 2.
  • Caution is warranted if concurrent use with other diabetic or weight-loss medications that may increase heart rate.
  • Medication cost, insurance coverage, access resources, and affordability impact who can receive Wegovy therapy in clinical practice.

Comparative Analysis with Other Weight Loss Treatments


Wegovy vs Ozempic

Wegovy’s active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It shares this mechanism with Ozempic, which is also semaglutide-based; however, Ozempic is specifically approved for glycemic control in type 2 diabetes rather than weight loss. While their action is similar, Wegovy contains a higher 2.4 mg dose of semaglutide compared to the 1mg dose in Ozempic. Head-to-head comparisons show Wegovy’s effects on appetite suppression and caloric reduction translate to nearly double the amount of weight lost.

Wegovy vs Saxenda

Saxenda is another GLP-1 receptor agonist injection, but it contains the related molecule liraglutide rather than semaglutide. Both Saxenda and Wegovy are injected on a weekly basis for weight control. However, across clinical studies, those taking Wegovy tend to lose around 15% of their starting body weight over the course of a year, while Saxenda patients average closer to 6% baseline weight loss. Clearly, Wegovy promotes improved weight outcomes.

Wegovy vs Orlistat/Xenical

Orlistat is an oral capsule medication taken up to three times per day with meals. Its mechanism differs from GLP-1 drugs in that it works in the GI tract to block some dietary fat absorption. While orlistat has a role for some patients, weight loss tends to be modest at best compared to Wegovy, with only 10% of patients losing 10% of their weight or more on orlistat based on research trials. In contrast, nearly 70% of those taking Wegovy long-term can attain this threshold of weight loss success.


Cost Considerations and Insurance Coverage


Insurance coverage for medications intended for weight loss, such as Wegovy, varies widely. Individuals with private or employer-sponsored health insurance might qualify to pay as little as $0 for a 28-day supply of Wegovy. Novo Nordisk, the manufacturer, provides a savings card that can cover up to $225 per month if the insurance plan covers Wegovy.


For those whose insurance doesn’t cover Wegovy, the typical cost ranges from $1,350 to $1,800 for a 28-day supply. Novo Nordisk offers a savings card that can offset up to $500 per 28-day supply for Wegovy if insurance doesn’t cover it. Eligible individuals might pay as little as $0 per month for up to 12 refills.

Contact Weight Loss Clinic  Los Angeles today to learn how our multi-modal plans, including Wegovy, can help you finally shed those stubborn pounds.


Wegovy Injections for Weight Loss Near Me


Weight Loss Clinic LA offers the best Wegovy Injections near me in Beverly Hills but can also come to your home or office throughout the Los Angeles area. We serve patients near Beverly Hills, Bel Air, West Hollywood, Santa Monica, West Los Angeles, Culver City, Hollywood, Venice, Marina del Rey, Malibu, Manhattan Beach, Redondo Beach, Downtown Los Angeles, Encino, Woodland Hills, Sherman Oaks, Calabasas, Burbank, Glendale, Hidden Hills, Agoura Hills, Northridge, North Hollywood, Topanga, Canoga Park, Reseda, Valley Glen, Chatsworth, West Hills, Winnetka, Universal City, Silverlake, Echo Park, and many more.


  1. Ghusn W, De la Rosa A, Sacoto D, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open. 2022;5(9):e2231982. Published 2022 Sep 1. doi:10.1001/jamanetworkopen.2022.31982
  2. Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5-13. doi:10.1136/jim-2021-001952
  3. Wegovy | European Medicines Agency. Europa.eu. Published March 10, 2022. Accessed December 7, 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
  4. Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5-13. doi:10.1136/jim-2021-001952
  5. Committee for Medicinal Products for Human Use (CHMP) Assessment Report Wegovy.; 2021. https://www.ema.europa.eu/en/documents/assessment-report/wegovy-epar-public-assessment-report_en.pdf

Book Appointment

"*" indicates required fields

Step 1 of 3

*Please use ZIP code that matches your Credit Card otherwise it will be declined.
Our Staff will contact you to Confirm and Schedule time of Appointment